Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509.

Publication Type:

Journal Article

Source:

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 6, Issue 11, p.1938-45 (2011)

Keywords:

2011, Center-Authored Paper, October 2011, Public Health Sciences Division

Abstract:

: Malignant pleural mesothelioma (MPM) tumors express vascular epithelial growth factor (VEGF) and VEGF receptors. We conducted a phase II study of the oral pan-VEGF receptor tyrosine kinase inhibitor, cediranib, in patients with MPM after platinum-based systemic chemotherapy.